Avian Influenza Vaccines Market
Number of pages: 100 | Report Format: PDF | Published date: March 31, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 142.12 million |
|
Revenue Forecast in 2031 |
US$ 205.81 million |
|
CAGR |
4.2% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Strain, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global avian influenza vaccine market was valued at US$ 142.12 million in 2021 and is expected to register a revenue CAGR of 4.2% to reach US$ 205.81 million by 2031.
Avian Influenza Vaccines Market Fundamentals
Avian influenza, or bird flu, is a disease caused by infection with avian (bird) influenza (flu) Type A viruses. These viruses propagate naturally among wild aquatic birds and can infect domestic poultry as well as other bird and mammal species. Normally, bird flu viruses do not infect humans. Human infections with bird flu viruses have occurred on an irregular basis. To control the spread of avian influenza in areas where outbreaks occur, it is common practice to slaughter all poultry, infected or healthy. As a result, farmers will suffer significant economic losses, with long-term consequences for their livelihoods. However, poultry is not the only one affected. While wild birds play an important part in the propagation of the disease, they are also victims of bird flu viruses. Avian influenza is also a big public health risk.
Influenza A virus is an eight-gene fragmented single-stranded negative-sense RNA virus. So far, 18 distinct hemagglutinins (HA, H1-H18) and 11 distinct neuraminidases (NA, N1-N11) have been identified, resulting in a massive pool of influenza viruses. Since 1959, highly pathogenic H5 and H7 subtype avian influenza viruses (AIVs) containing various NA subtypes have caused several illness outbreaks in poultry and wild birds worldwide. South China has long been thought to be the world's known epicenter for the genesis of pandemic influenza viruses. The Ministry of Agriculture and Rural Affairs has been vaccinating chickens, ducks, geese, and other live poultry kept on live poultry farms in Nanchang with the H5 + H7 AIV vaccine since September 2017. Farmed live birds typically receive their first vaccination dosage at 10 days of age, a second dose at one month, and a third dose at three months. As a result, in response to the rapidly spreading subtype AIV, everyone should focus on more long-term and effective strategies other than immunizations to reduce AIV spread. For example, daily washing and cleaning of slaughtering utensils, weekly disinfection of the environment, separate placement of different types of live poultry such as waterfowl and land poultry, and monthly closure of live poultry markets can all help to reduce the risk of AIV pollution at the source.
[69867]
Avian Influenza Vaccines Market Dynamics
The increase in disease frequency in emerging nations is driving market revenue growth. Infections are becoming widespread in emerging nations, potentially increasing poultry mortality. At the same time, the rising human consumption of chicken necessitates greater research to create effective disease-prevention vaccinations. Chickens can be made resistant to avian flu using gene editing techniques. Furthermore, specific regulation allows for the eradication of hen bird flu.
Another key element influencing the revenue CAGR of the global avian influenza vaccines market is growing healthcare spending, which aids in infrastructure improvement. Furthermore, several government organizations intend to improve healthcare infrastructure by increasing financing, which would have an impact on the market dynamics. Furthermore, increased public and private sector attempts to raise awareness about avian influenza, as well as rising healthcare spending, will drive the avian influenza vaccines market revenue growth to some extent. Furthermore, rising consumer demand for chicken and an increase in outbreaks will drive the market revenue growth for the global avian influenza vaccines.
During the forecast period, the growing number of strategic alliances will provide new and valuable market possibilities. Strategic collaboration between commercial and government organizations in the development of healthcare solutions, as well as collaborative efforts in the digitization of medical aid facilities, might help the sector thrive.
Furthermore, increased investment in advanced technology research and an increase in emerging markets will give further chances for avian influenza vaccines market revenue growth during the forecast period. On the other hand, the enormous expenses involved with medicine distribution and development will stymie market revenue expansion. The absence of healthcare infrastructure in emerging nations, as well as a scarcity of experienced specialists, would provide a hurdle to the market for avian influenza vaccines. Furthermore, the lack of effective vaccination and a lack of knowledge among poultry keepers would be a restraining factor and further hamper the market revenue growth rate during the forecast period.
Favorable initiatives taken by government agencies and animal associations are expected to supply significant growth prospects for players in the global avian influenza vaccines market. For instance, the World Health Organization (WHO) has identified antimicrobial resistance as a public health threat. Many public health bodies and veterinary regulatory agencies, such as the Committee for Medicinal Products for Veterinary Use (CVMP), are accountable for realizing the European Union's One Health Action Plan against antimicrobial resistance by deploying certain policies of the Veterinary Medicines Regulation.
Avian Influenza Vaccines Market Ecosystem
The global avian influenza vaccine market has been analyzed from four perspectives: type, strain, application, and region.
Avian Influenza Vaccines Market by Type
[856765]
Based on type, the global avian influenza vaccines market is segmented into combination vaccines, inactivated vaccines, and live recombinant vaccines.
The inactivated vaccines segment showed lucrative revenue growth during the forecast period. The most popular method of producing flu vaccinations is using an egg-based manufacturing technique that has been utilized for over 70 years. Inactivated (killed) vaccines and live attenuated (weakened virus) vaccines are both produced via egg-based vaccine production. The egg-based manufacturing method begins with the CDC or another laboratory partner in the WHO Global Influenza Surveillance and Response System supplying candidate vaccine viruses (CVVs) generated in chicken eggs in accordance with existing FDA regulatory standards to private sector producers. These CVVs are then injected into fertilized chicken eggs and allowed to proliferate for many days. The virus-containing fluid is extracted from the eggs. These vaccines are produced by inactivating (killing) the vaccine viruses and purifying the viral antigen. Quality testing, packaging, and distribution are all part of the production. Several producers employ egg-based manufacturing methods to create flu vaccinations for usage in the United States. This technique of vaccine manufacturing involves chicken eggs and may take longer than other procedures.
Avian Influenza Vaccines Market by Strain
Based on the strain, the global avian influenza vaccines market is segmented into H5, H7, and H9 strains.
The most frequently discovered avian influenza subtypes of Human infections have been caused by the H5, H7, and H9 strains. The bulk of avian influenza cases have been caused by the A(H5N1) and A(H7N9) (H5 and H7) viruses. Virus infections in humans have been recorded, with HPAI A(H5N6) and LPAI A(H9N2) viruses producing human illnesses in recent years. Human infections with various subtypes have been discovered in a small number of persons, including A(H6N1), A(H10N3), A(H10N7), and A(H10N8).
Avian Influenza Vaccines Market by Application
Based on application, the global avian influenza vaccines market is segmented into chicken, turkey, duck, and goose.
The chicken segment accounts for lucrative revenue growth during the forecast period. Domesticated bird chickens may become infected with avian influenza A viruses by direct contact with diseased waterfowl or other infected poultry or through contact with surfaces that have been contaminated with the viruses.
Avian Influenza Vaccines Market by Region
Based on region, the global avian influenza vaccines market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa.
The avian influenza vaccines market is expected to be dominated by Asia Pacific and the Middle East due to increased chicken production and growth in avian influenza outbreaks in the region. According to a recent Foreign Agricultural Service/USDA study, China produced 13,800 thousand metric tons of chicken meat in 2019. Furthermore, many government programs that provide timely and effective responses to emerging zoonotic influenza viruses are expected to fuel market revenue expansion.
During the forecast period, the European market for avian influenza vaccination is expected to account for the second-largest revenue share. The region's increased reliance on chicken as the primary source of protein in the diet is likely to drive regional market growth. The European Union (EU) produced 15.2 million tons of chicken meat in 2018, according to the European Commission. Furthermore, increased veterinary product manufacturing and enhanced animal husbandry practices in Germany and Poland support market revenue expansion.
During the forecast period, North America is expected to account for a considerable market revenue expansion due to the region's expanding meat and poultry industries, rising animal health expenditures, and the existence of a high number of veterinary institutions. Furthermore, increased government support for raising knowledge about avian influenza viruses and enhancing vaccination efficiency is favorably impacting market revenue growth.
Competitive Landscape for Avian Influenza Vaccines Market
The players in the avian influenza vaccines market are engaging in various growth strategies such as collaborations, partnerships, agreements, mergers, and acquisitions to enhance the market presence. Some of the prominent companies in the global avian influenza vaccines market include,
Strategic Developments in Avian Influenza Vaccines Market
Avian influenza, also known as bird flu, is a disease caused by infection with avian (bird) influenza (flu) Type A viruses. These viruses propagate naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and mammal species.
The expected size of the global avian influenza vaccine market in 2031 will be 205.81 million.
The expected revenue CAGR of the global avian influenza vaccines market during the forecast period is 4.2%.
Some of the prominent market players in the global avian influenza vaccines include QianYuanHao Biological Corporation Limited, Bayer AG, and Ringpu Bio-Technology Co., Ltd
The inactivate vaccine segment leads the global avian influenza vaccines market.
*Insights on financial performance are subject to the availability of information in the public domain